Extended-release quetiapine fumarate (quetiapine XR) monotherapy and quetiapine XR or lithium as add-on to antidepressants in patients with treatment-resistant major depressive disorder

Journal of Affective Disorders

Volumn 151, Issue 1, 2013, Pages 209-219

  Bauer, Michael ^a   Dell'Osso, Liliana ^b   Kasper, Siegfried ^c   Pitchot, William ^d   Vansvik, Eva Dencker ^e   Köhler, Jurgen ^e   Jørgensen, Leif ^f   Montgomery, Stuart A ^g  

^a UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^b UNIVERSITY OF PISA   (Italy)

^c MEDICAL UNIVERSITY OF VIENNA   (Austria)

^d UNIVERSITY OF LIÈGE   (Belgium)

^e ASTRAZENECA   (United Kingdom)

^f ASTRAZENECA R AND D   (Sweden)

^g IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

Atypical antipsychotic; Augmentation; Lithium; Major depressive disorder; Quetiapine XR; Treatment resistant depression

Indexed keywords

ANTIDEPRESSANT AGENT; CHOLESTEROL; CITALOPRAM; ESCITALOPRAM; GLUCOSE; LITHIUM; PAROXETINE; QUETIAPINE; SERTRALINE; TRIACYLGLYCEROL; VENLAFAXINE;

ADULT; ARTICLE; BODY WEIGHT; CHOLESTEROL BLOOD LEVEL; CLINICAL GLOBAL IMPRESSION SCALE; CONTROLLED STUDY; DEPRESSION; DIARRHEA; DIZZINESS; DRUG DOSE TITRATION; DRUG WITHDRAWAL; FATIGUE; FEMALE; HEADACHE; HUMAN; LETHARGY; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MONOTHERAPY; MONTGOMERY ASBERG DEPRESSION RATING SCALE; NAUSEA; OPEN STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REMISSION; SCORING SYSTEM; SEDATION; SIDE EFFECT; SOMNOLENCE; TREMOR; VERTIGO; VOMITING; XEROSTOMIA;

ATYPICAL ANTIPSYCHOTIC; AUGMENTATION; LITHIUM; MAJOR DEPRESSIVE DISORDER; QUETIAPINE XR; TREATMENT-RESISTANT DEPRESSION;

ADOLESCENT; ADULT; AGED; ANTIDEPRESSIVE AGENTS; ANTIPSYCHOTIC AGENTS; DELAYED-ACTION PREPARATIONS; DEPRESSIVE DISORDER, MAJOR; DEPRESSIVE DISORDER, TREATMENT-RESISTANT; DIBENZOTHIAZEPINES; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; LITHIUM; LITHIUM COMPOUNDS; MALE; MIDDLE AGED; PSYCHIATRIC STATUS RATING SCALES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84888641330     PISSN: 01650327     EISSN: 15732517     Source Type: Journal    
DOI: 10.1016/j.jad.2013.05.079     Document Type: Article

References (48)

1. Astrazeneca. Sero quel XR (quetiapine fumarate) Extended-release Tablets-US Prescribing Information. 2010. Available at: Http://wwwI.astrazeneca- us. com/pi/seroquelxr.pdf) (accessed April 26, 2012)
2. Bauer, M., El-Kh alili, N., Datto, C., Szamosi, J., Eriksson, H., 2010a. A pooled analysis of two randomised, placebo-controlled studies of extended release quetiapine fumarate adjunctive to antidepressant therapy in patients with major depressive disorder. Journal of Affective Disorders 127, 19-30
3. Bauer, M., Adli, M., Bschor, T., Pilhatsch, M., Pfennig, A., Sasse, J., Schmid, R., Lewitzka, U., 2010b. Lithiums emerging role in the treatment of refractory major depressive episodes: Augmentation of antidepressants. Neuropsychobiology 62, 36-42
4. Bauer, M., Bschor, T., Pfennig, A., Whybrow, RC, Angst, J., Versiani, M., MaIler, H.J., 2007. world Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of unipolar depressive disorders in primary care. The world Journal of Biological Psychiatry 8, 67-104.
5. Bauer M. Pfennig A. Severus E. whybrow RC. Angst J. MaIler H.J. Task Force on Unipolar Depressive Disorders 2013. world Federation of Societies of Biological Psychiatry (wFSBP) guidelines for biological treatment of u nipolar depressive disorders, part 1: Update 2013 on the acute and continuation treatment of unipolar depressive disorders The world Journal of Biological Psychiatry Early Online 1-52
6. Bauer, M., Pretorius, H.w., Co nstant, E.I., Earley, w.R., Szamosi,J., Brecher, M., 2009. Extended-release quetiapine as adjunct to an antidepressant in patients with major depressive disorder: Results of a randomized, placebo-controlled, double-blind study. Journal of Clinic al Psychiatry 70, 540-549
7. Baumann, R, 1996. Pharmacokinetic-pharmacodynamic relationship of the selective serotonin reuptake inhibitors. Clinical Pharmacokinetics 31, 444-469
8. Beck, A.T., ward, CH., Mendelson, M., Mock, J., Erbaugh, J., 1961. An inventory for measuring depression. Archives of General Psychiatry 4, 561-571
9. Berman, R.M., Fava, M., Thase, M.E., Trive di, M.H., Swanink, R., McQuade, R.D., Carson, w.H., Adson, D., Taylor, I., Hazel, J., Marcus, R.N., 2009. Aripiprazole augmentation in major depressive disorder: A double-blind, placebo-controlled study in patients with inadequate re sponse to antidepressants. CNS Spectrums 14, 197-206
10. Berman, RM., Marcus, R.N., Swanink, R., McQuade, R.D., Carson, w.H., Corey-Lisle, R K., Khan, A., 2007. The efficacy and safety of aripiprazole as adjun ctive therapy in major depressive disorder: A multIcenter, randomized, double-blind, placebo-controlled study. Journal of Clinical Psychiatry 68, 843-853
11. Calabrese, J.R., KeckJr., RE., Macfadden, w., Minkwitz, M., Ketter, T.A., weisler, R.H., Cutler, A.J., McCoy, R.N., wilson, E., Mullen, J., 2005. A randomized, double-blind, placebo-controlled trial of quetiapine in the treatment of bipolar 1 or 11 depression. The American Journal of Psychiatry 162, 1351-1360
12. Crossley, N.A., Bauer, M., 2007. Acceleration and augmentation of antidepressants with lithium for depressive disorders: Two meta-analyses of randomized, placebo-controlled trials. Journal of C linical Psychiatry 68, 935-940
13. Crown, w.H., Finkelstein, S., Berndt, E.R., Ling, D., Poret, A.w., Rush, A.J., Russell, J. M., 2002. The impact of treatment-resistant depression on health care utilization and co sts. Journal of Clinical Psychiatry 63, 963-971
14. Cutler, A.J., Montgomery, S.A., Feifel, D., Lazarus, A., Astrom, M., Brecher, M., 2009. Extended release quetiapine fumarate monotherapy in major depressive disorder: A placebo-and duloxetine-controlled study. Journal of Clinical Psychiatry 70, 526-539
15. Detke, M.J., Lu, Y., Goldstein, D.J., Hayes, J.R., Demitrack, M.A., 2002. Duloxetine, 60 mg once daily, for major depressive disorder: A randomized double-blind placebo-controlled trial. Journal of Clinical Psychiatry 63, 308-31S
16. El-Khalili, N., Joyce, M., Atkinson, S., Buynak , R.J., Datto, C, Lindgren, R, Eriksson, H., 2010. Extended-release quetiapine fumarate (quetiapine XR) as adjunctive therapy in major depressive disorder (MDD) in patients with an inadequate response to ongoing antidepressant treatment: A multIcentre, randomized, double-blind, placebo-controlled study. The International Journal of Neuropsychopharmacology 13, 917-932
17. Fava, M., 2003. Diagnosis and definition of treatment-resistant depression. Biological Psychiatry 53, 649-659
18. Feeny, D., Furlong, w., Boyle, M., Torrance, G.w., 1995. Multi-attribute health status classification systems. Health Utilities Index Pharmacoeconomics 7, 490-502
19. Guy, w., 1976. ECDEU Assessment Manual for Psychopharmacology. US National Institute of Health, Rockville, MD
20. Jensen, N.H., Rodriguiz, RM., Caron, M.G., wetsel, w.C., Rothman, R.B., Roth, B.I., 2008. N-desalkylquetiapine, a potent norepinephrine reuptake inhibitor and partial 5-HT(IA) agonist, as a putative mediator of quetiapines antidepressant activity. Neuropsychopharmacology 33, 2303-2312.
21. Joffe R.T. Singer w. Levitt A.J. MacDonald C.1993. A placebo-controlled comparison of lithium and triiodothyronine augmentation of tricyclic anti-depressants in unipolar refractory depression Archives of General Psychiatry 50 387-393
22. Katona, CL, Abou-Saleh, M.T., Harrison, D.A., Nairac, BA., itawaras, U.K., LOCK, i., Burns, R.A., Robertson, MM., 1995. Placebo-controlled trial of lithium augmentation of fluoxetine and lofepramine. The British Journal of Psychiatry 166, 80-86
23. Kindler, CH., Harms, C., Amsler, F, lhde-Scholl, T., Scheidegger, D., 2000. The visual analog scale allows effective measurement of preoperative anxiety and detection of patients' anesthetic concerns. Anesthesia & Analgesia 90, 706-712
24. Liebowitz, M., Lam, R.w., Lepola, U., Datto, C., Sweitzer, D., Eriksson, H., 2010. Efficacy and tol erability of extended release quetiapine fumarate monotherapy as maintenance treatment of major depressive disorder: A randomized, placebo-controlled trial. Depression and Anxiety 27, 964-976
25. Machado-Vieira, R, Salvadore, G., Luckenbaugh, D.A., Manji, H.IC, Zarate, CA., 2008. Rapid onset of antidepressant action: A new paradigm in the research and treatment of major depressive disorder. Journal of Clinical Psychiatry 69, 946-958
26. Mahmoud, R.A., Pandina, G.J., Turkoz, L., Kosik-Gonzalez, C., Canuso, CM., Kujawa, M.J., Gharabawi-Garibaldi, G.M., 2007. Risperidone for treatment-refractory major depressive disorder: A randomized trial. Annals of Inte rnal Medicine 147, 593-602
27. Marcus, RN., McQuade, RD., Carson, w.H., Hennicken, D., Fava, M., Simon, J.S., Trivedi, M.H., Thase, ME., Berman, R.M., 2008. The efficacy and safety of aripiprazole as adjunctive thera py in major depressive disorder: A second multIcenter, randomized, double-blind, placebo-controlled study. Journal of Clinical Psychopharmacology 28, 156-16S
28. McElroy, S.I., weisler, RH., Chang, w., Olausson, B. , Paulsson, B., Brecher, M., Agambaram, V., Merideth, C, Nordenhem, A., Young, A.H., 2010. A double-blind, placebo-controlled study of quetiapine and paroxetine as monotherapy in adults with bipolar depression (EMBOLDEN 11). Journal of Clinical Psychiatry 71, 163-174
29. Melander, H., Salmonson, T., Abadie, E., Van Zwieten-Boot, B., 2008. A regulatory Apologia-a review of placebo-controlled studies in regulatory submissions of new-generation antidepressants. European Neuropsychopharmacology 18, 623-627
30. Mendlewicz, J., 2009. Sleep disturbances: Core symptoms of major depressive disorder rather than associated or comorbid disorders. The world Journal of Biological Psychiatry 10, 269-27S
31. Montgomery, S.A., Asberg, M., 1979. A new depression scale designed to be sensitive to change. The British Journal of Psychiatry 134, 382-389.
32. Montgomery S.A. Bech R Blier R MaIler H.J. Nierenberg A.A. Pinder R.M. Quitkin FM. Reimitz RE. Rosenbaum J.F. Rush A.J. Stassen H.H. Thase ME. 2002. Selecting meth odologies for the evaluation of differences in time to response between antidepressants Journal of Clinical Psychiatry 63 694-699
33. Montgomery, S.A., MaIler, H.J., 2009. Is the significant superiority of escitalopram compared with other antidepressants clinically relevant? International Clinical Psychopharmacology 24, 111-118
34. Nemeroff, C.B., 2007. PrevaLence and management of treatment-resistant depression. Journal of Clinical Psychiatry 68 (Suppl. 8), 17-2S
35. Nyberg, S., widzowski, D., 2010. Translational pharmacology of quetiapine and norquetiapine: Preclinical findings support multifianctional psychotropic properties. European Psychiatry 25 (Suppl. 1)1446, abs PwOl-27
36. Papakostas, G.I., 2009. Managing partial response or nonresponse: Switching, augmentation, and combination strategies for major depressive disorder. Journal of Clinical Psychiatry 70, 16 2S
37. Rosenbaum, J.F., Zajecka, J., 1997. Clinical management of antidepressant discontinuation. Journal of Clinical Psychiatry 58 (Suppl. 7), 37-40
38. Rush, A.J., Trivedi, M.H., wisniewski, S.R, Nierenberg, A.A., Stewart, .w., warden, D., Niederehe, G., Thase, ME., Lavori, Rw., Lebowitz, B.D., McGrath, RJ., Rosenbaum, J.F, Sackeim, HA., Kupfer, D.J., Luther, J., Fava, M. , 2006. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: A STAR D report The American Journal of Psychiatry 163, 1905-1917
39. Sheehan, DV., Lecrubier, Y., Sheehan, ICH., Amorim, R, Janavs, J., weiller, E., Hergueta, T., Baker, R., Dunbar, G.C., 1998. The mini-international neuropsychiatric interview (MINI.): The development and validation of a structured diagnostic psychiatric inter view for DSM-IV and LCD-b. Journal of Clinical Psychiatry 59 (Suppl. 20), 22-33
40. Shelton, RC., 2007. Augmentation strategies to increase antidepressant efficacy. Journal of Clinical Psychiatry 68 (Suppl. 10), 18-22
41. Thase, ME., 2009. Update on partial response in depression. Journal of Clinical Psychiatry 70 (Suppl. 6), 4-9
42. Thase, ME., Corya, S.A., Osuntokun, O., Case, M., Henley, D.B., Sanger, TM., Watson, SB., Dube, S., 2007. A randomized, double-blind comparison of olanzapine/fluoxetine combination, olanzapine, and fluoxetine in treatment-resistant major depressive disorder. Journal of Clinical Psychiatry 68, 224-236
43. Thase, ME., Macfadden, w., weisler, RH., Chang, W., Paulsson, B., Khan, A., Calabrese, JR., 2006. Efficacy of quetiapine monotherapy in bipolar 1 and 11 depression: A double-blind, placebo-contr olled study (the BOLDER 11 study). Journal of Clinical Psychopharmacology 26, 600-609
44. Thase, ME., Rush, A.J., 1997. when at first you don't succeed: Sequential strategies for antidepressant nonresponder s. Journal of Clinical Psychiatry 58 (Suppl. 13), 23-29
45. Ware, Jr., J.E., Sherbourne, CD., 1992. The MOS 36-item short-form health survey (SF-36). L. Conceptual framework and item selection. Medical Care 30, 473-483
46. vveisier, it., Joyce, IV., ivicum, L, Lazarus, A., Szamosi,J., Eriksson, H., 2009. Extended release quetiapine fumarate monotherapy for major depressive disorder: Results of a double-blind, randomized , placebo-controlled study. CNS Spectrums 14, 299-313
47. Young, A.H., McElroy, S.I., Bauer, M., Philips, N., Chang, W., Olausson, B., Paulsson, B., Brecher, M., 2010. A double-blind, pl acebo-controlled study of quetiapine Zullino, and lithium monotherapy in adults in the acute phase of bipolar depression (EMBOLDEN 1). Journal of Clinical Psychiatry 71, 150-162
48. Zullino, D., Baumann, P., 2001. Lithium augmentation in depressive patients not responding to selective serotonin reuptake inhibitors. Pharmacopsychiatry 34, 119-127